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ABSTRAK
Karsinoma sel hati (KSH) adalah penyebab kematian akibat kanker yang kedua tertinggi di dunia. Hal ini 
disebabkan oleh heterogenitas biologis tumor dan terbatasnya pilihan pengobatan kuratif. Faktor prognostik 
yang paling signifikan adalah deteksi kanker pada stadium awal. Oleh karena itu, strategi surveilans sangat 
penting. Pasien yang berisiko tinggi terkena kanker hati harus menjalani pemeriksaan ultrasonografi (USG) 
dan pemeriksaan penanda tumor setiap enam bulan sekali untuk mendeteksi KSH pada stadium awal. Akan 
tetapi, dalam praktik sehari-hari, USG memiliki beberapa keterbatasan.  Di samping itu, kepatuhan terhadap 
surveilans KSH juga tidak optimal karena berbagai alasan, baik dari sisi penyedia layanan kesehatan, pasien, 
maupun sistem pelayanan kesehatan. Pada artikel ini, kami akan membahas mengenai metode surveilans KSH 
terkini dan hambatan yang didapatkan dalam praktik sehari-hari.
Kata kunci: karsinoma sel hati, surveilans, ultrasonografi, penanda tumor, deteksi dini.
ABSTRACT
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide. 
This is due to the heterogeneity of the tumor biology and lack of curative treatment options. The most significant 
prognostic factor is detection at early stage and thus, surveillance strategies are of high importance. High-risk 
patients should undergo ultrasound and tumor marker tests at six-month interval in order to detect HCC at 
the earlier stage. However, in real-life practice, ultrasound has several limitations and the adherence to HCC 
surveillance is suboptimal due to various provider, patient, and health-care system factors. In this paper, we 
will address current methods of HCC surveillance and obstacles found in real-life practice.
Keywords: hepatocellular carcinoma, surveillance, ultrasound, tumor markers, early detection.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the 
fifth most common cancer and the second most 
common cause of cancer-related death in the 
world.1 The overall ratio of mortality due to 
liver cancer to incidence was 0.95 and most 
liver cancer (83%) was diagnosed in less well 
developed nations.1 The dismal prognosis of this 
cancer was due to its aggressive nature and poor 
survival. Despite major progress in treatment, the 
prognosis of HCC globally remains poor, because 
a greater number of patients with HCC may be 
asymptomatic until they are in the late-stage of 
the disease, which prevent them from receiving 
potentially curative treatment. When patients 
receive potentially curative therapy in the form 
of liver transplantation, surgical resection, or 
tumor ablation, a considerable improvement in 
survival is achieved (five years survival rate, 
40%-70%).2-4 Therefore, regular surveillance in 
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high-risk population is the key for early diagnosis 
and improvement of HCC patient survival. This 
paper will review the approach to surveillance for 
HCC in high-risk patients and follow-up testing 
for lesions found during surveillance.
EPIDEMIOLOGY OF HCC
Hepatocellular carcinoma is the most 
common primary cancer of the liver and the 
second most common cause of cancer-related 
death. The incidence of HCC is estimated to 
be 554 000 cases per year in men, causing 
nearly a similar number of deaths globally per 
year. The regions of highest HCC incidence 
rates are Eastern and South-Eastern Asia, with 
estimated age-standardized rates >20 per 100,000 
population.1 Although currently low in the United 
States, the incidence of HCC has tripled since the 
early 1980s with the largest increase occurred 
among Hispanics followed by blacks and non-
Hispanic whites.5 The age distribution of HCC 
varies by region, gender, and etiology.6 The rate 
of HCC in men is greater than that of women, 
with the male to female ratio ranging between 2:1 
and 4:1, with the difference being much greater 
in high-risk areas.
Chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections are the main 
etiology of HCC cases, with chronic hepatitis 
B (CHB) infection being the major cause in 
all Asia-Pacific countries, except for Japan. In 
Japan, chronic hepatitis C (CHC) infection is 
the most common etiology of HCC, representing 
up to 70% of cases.7 However, there is also a 
substantial population of HCC patients (5-20%) 
who are negative for both markers of hepatitis 
B virus and hepatitis C virus infection [non-B, 
non-C (NBNC) hepatitis] in Japan and the 
incidence of NBNC-HCC has recently tended 
to increase.8 In Western countries and Africa, 
HCV is also a major cause of HCC, in addition to 
alcoholic liver disease, and possibly nonalcoholic 
fatty liver disease (NAFLD).9
The prognosis of liver cancer is unfavorable 
in most patients with HCC, even in developed 
countries. Patients with advanced HCC who 
are only eligible for palliative treatment have 
a median survival of less than one year,10,11 
while those who are diagnosed in early-stage 
can achieve 5-year survival rates of 70% with 
potentially curative treatment, such as transplant 
or resection.12 Therefore, HCC surveillance 
has been recommended to detect HCC at an 
early stage, when curative treatment can be 
administered.
HCC SURVEILLANCE RECOMMENDATIONS
Target Population
The major risk factor for the development 
of HCC is liver cirrhosis, which is mainly 
caused by HBV, HCV, alcoholic liver disease, 
and NAFLD. Cirrhosis is present in about more 
than 80% of patients with HCC.13 The risk of 
HCC in cirrhotic patient is not uniform because 
different etiologies of cirrhosis are associated 
with different incidence of HCC. HCV infection 
is associated with the highest HCC incidence 
in cirrhotic patients, with a 5-year cumulative 
incidence as high as 30%.14 In HBV-associated 
cirrhosis, the 5-year cumulative HCC risk is 15% 
in high endemic areas and 10% in the West, while 
in alcoholic cirrhotics, the 5-year cumulative 
risk is 8%.14 However, there is limited data 
on HCC risk in NAFLD-associated cirrhosis. 
Additional risk factors for developing HCC 
include intake of aflatoxin-contaminated food, 
diabetes, obesity, certain hereditary conditions 
such as hemochromatosis, and various metabolic 
disorders.15,16 These additional risk factors may 
influence decision making for offering HCC 
surveillance.
Current Guidelines
Surveillance for hepatocellular carcinoma 
(HCC) have already been described in guidelines 
published by the American Association for 
the Study of Liver Diseases (AASLD),17 the 
European Association for the Study of the Liver 
and the European Organisation for Research and 
Treatment of Cancer (EASL-EORTC),18 and 
the Japan Society of Hepatology (JSH).19 The 
AASLD practice guideline on the management 
of hepatocellular carcinoma states that high-risk 
population is defined as those with cirrhosis and 
those with chronic HBV infection regardless 
of cirrhosis (Table 1). The EASL-EORTC 
guidelines also recommend surveillance in 
chronic hepatitis C patients and advanced liver 
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fibrosis.20 This is supported by a study in the 
United States that found HCC occurrence in 
patients with chronic hepatitis C and bridging 
fibrosis in the absence of cirrhosis (Metavir F3).21 
However, the guidelines do not recommend 
Child-Pugh C cirrhotic patients to obtain regular 
surveillance, except when those patients are in 
the transplant-waiting list.20
The JSH guideline classifies patients into 
high-risk group (patients with chronic hepatitis 
B/C or cirrhosis) and a super high-risk group 
(patients with hepatitis B/C cirrhosis). For 
super high-risk group, it is recommended that 
dynamic computed tomography (CT)/ magnetic 
resonance imaging (MRI) be performed every 
6-12 months. The sensitivity of MRI to detect 
curable HCC lesion is significantly higher than 
that of ultrasonography.22 However, this modality 
is limited by the high-cost and resources needed. 
Cost-effectiveness of a cancer-screening program 
depends not only on the test’s performance, but 
also the test’s cost and the availability of treatment 
modalities that significantly prolong survival.23,24
Surveillance Tests
Modalities that can be used for HCC 
surveillance tests comprise of imaging and 
serological tests. Ultrasonography is the most 
widely used imaging test for surveillance. The 
sensitivity of US for detecting tumors before 
they present clinically, was 94%, but US was 
less effective for identifying early HCC, with a 
sensitivity of 63%.25 When US was combined 
with alpha-feto protein (AFP), there was an 
insignificant increase of sensitivity to 69%.25 
A retrospective study from Japan found that 
ultrasound (US) surveillance at 6-month intervals 
performed by highly skilled operators was able 
to detect tumors of 1.6 ± 0.6 cm.26 However, in 
real clinical practice, the sensitivity of ultrasound 
alone as a surveillance program was 44%, while in 
combination with AFP, the sensitivity improved 
significantly to 90%.27 The characteristics of 
liver cirrhosis, which include fibrous septa and 
regenerative nodules, produce a course pattern 
on US, which may decrease the ability of US to 
detect small tumors. Furthermore, ultrasound is 
reported to be less accurate in visualizing the 
liver in patients with morbid obesity.28,29
The serological test that most widely used in 
clinical practice is serum AFP. However, AFP has 
several limitations as a surveillance test. Firstly, 
AFP levels may be fluctuating in patients with 
cirrhosis, especially in those with exacerbation 
of underlying liver disease.30 Secondly, only less 
than 20% of tumors present with abnormal serum 
AFP level at early stage.31 At the level of 10 ng/
mL, the sensitivity and specificity of AFP was 
77% and 78%, respectively.32
Other serological tests for HCC surveillance 
are protein-induced by vitamin K absence or 
antagonist-II (PIVKA-II), also known as Des-
γ-carboxy-prothrombin (DCP), and AFP lectin 
fraction (AFP-L3). These serological tests are 
usually used in combination and are routinely 
used in Japan.19 The available evidence regarding 
these serological tests in the surveillance setting 
is still inconclusive. In a French study, at a cut-
off of 42 mAu/mL, PIVKA-II had a sensitivity 
and specificity of 77% and 82%, respectively, 
versus 61% and 50% for AFP at a cut-off of 5.5 
ng/mL, for the diagnosis of early HCC.33 An 
observational study from South Korea found 
that at a cut-off of 10 ng/mL, AFP was the best 
single biomarker in diagnosing HCC. However, 
the diagnostic value of AFP was improved by 
Table 1. High-risk groups for whom hepatocellular 
carcinoma (HCC) surveillance is recommended
Population at risk HCC risk per year
Cirrhosis
 - Hepatitis B 3–8%
 - Hepatitis C 3–5%
 - Primary biliary cirrhosis 3–5%
 - Non-alcoholic 
steatohepatitis NA
 - Genetic 
hemochromatosis NA
 - Alpha-1 antitrypsin 
deficiency
NA
 - Autoimmune hepatitis NA
Hepatitis B positive without cirrhosis (Hepatitis B 
surface antigen positive)
 - Asian male >40 years 0.4–0.6%
 - Asian female >50 
years 0.3–0.6%
 - Africans >20 years NA
 - Family history of HCC NA (incidence higher than without family history)
NA = not available
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combining it with PIVKA-II (>40 mAU/mL), 
but adding AFP-L3 (>10%) did not contribute 
to the capacity to distinguish between HCC and 
non-HCC.34 Another study by Lim et al35 found 
that PIVKA-II was superior to AFP or AFP-L3 in 
detecting overall HCC and combining PIVKA-II 
with the other two tests resulted in better accuracy 
than PIVKA-II alone.35 In contrary, Durazo et al 
found that PIVKA-II had the highest sensitivity 
for HCC diagnosis and combining two or three 
markers of HCC did not give significant benefit. 
This discrepancy might be related to different 
etiologies and study population.36 Durazo et 
al.36 included similar number of hepatitis B and 
hepatitis C, and defined chronic viral hepatitis 
with or without cirrhosis as a control group, 
while Lim35 only included cirrhotic patients with 
hepatitis B as the dominant etiology.
Interval of HCC surveillance
A 6-month interval is currently recommended 
by AASLD and EASL-EORTC guidelines, but 
the Japanese guidelines propose a 3-4-month 
interval in super-high-risk patients (hepatitis 
B-related liver cirrhosis and hepatitis C-related 
liver cirrhosis). Based on median HCC volume 
doubling time, which is reported to be 85 – 171 
days,37-39 a 6-month interval is a reasonable 
choice. One randomized-controlled trial 
(RCT) comparing ultrasound performed at 
3- or 6-month intervals showed no significant 
difference in HCC detection rate between the 
two groups.40 However, when compared with 
12-month interval, a 6-month interval gave better 
performance in terms of stage migration41 and 
survival.42 A meta-analysis also demonstrated a 
better sensitivity for ultrasound to detect early 
HCC in 6-month interval than in 12-month 
interval.25
Recall Policy
A recall policy is of highly importance 
in dealing with an abnormal finding during 
routine ultrasound or serological tests. Abnormal 
ultrasound results are a newly detected focal 
lesion or a known hepatic lesion that enlarges 
and/or changes its echo pattern.43 Increase of 
AFP, PIVKA-II, or AFP-L3 serum level should 
also raise a suspicion of HCC in the absence of 
focal lesion detected during ultrasound.44 When a 
surveillance test is abnormal, the next diagnostic 
tests are triple-phase or triphasic abdominal CT 
or MRI. Triple-phase technique acquires images 
at three different time points, or phases, following 
the administration of contrast agent, i.e. arterial 
phase, portal-venous phase, and delayed phase. 
The radiological hallmark of HCC is the presence 
of contrast uptake (enhancement) in the arterial 
phase and washout in the portal venous or 
delayed phase. Finding of a liver mass with this 
radiological hallmark in a cirrhotic patient is 
considered diagnostic for HCC (Figure 1). We 
propose an algorithm, which is adapted from the 
Japanese, EASL, and AASLD guidelines, and are 
currently used in Indonesia.45
Atypical focal hepatic mass should be 
evaluated further by conducting biopsy or MRI 
with liver-specific contrast. Liver specific MRI 
contrast agent is gadolinium ethoxybenzyl 
dimeglumine (Gd-EOB-DTPA, Primovist 
in Europe and Eovist in the USA), which 
has up to 50% hepatobiliary excretion in the 
normal liver. After intravenous injection, Gd-
EOB-DTPA distributes into the vascular and 
extravascular spaces during the arterial, portal 
venous, and delayed phases, and increasingly 
into the hepatocytes and bile ducts during the 
hepatobiliary phase.46 If Gd-EOB-DTPA-MRI 
shows a hypervascular mass during arterial phase 
without venous washout, a diagnosis of HCC can 
be made if the mass shows hypointensity in the 
hepatobiliary phase of Gd-EOB-DTPA-MRI.44 
Biopsy is sometimes difficult to be done in small 
nodules which is not visualized during ultrasound 
examination. Contrast-enhanced ultrasound 
(CEUS) is also an alternative examination for 
atypical focal hepatic mass. Decreased uptake 
in the Kupffer phase on CEUS is indicative for 
HCC.47
If diagnosis of HCC is not established, it is 
recommended to repeat Gd-EOB-DTPA MRI or 
triple-phase CT/MRI and tumor biomarkers three 
months later. When there is no evidence of tumor 
growth, the patient continues routine surveillance 
tests every six months. If growth is present, MRI 
with liver-specific contrast or biopsy or CEUS 
may be repeated or the tumor is treated as HCC.
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EFFICACY OF HCC SURVEILLANCE
There are two randomized controlled trials 
that have been published on HCC surveillance. 
The first study was conducted in a population of 
nearly 19,000 Chinese patients with chronic HBV 
infection, regardless of the presence of cirrhosis.48 
In this study, the patients were randomized to 
US and AFP measurements every six months 
versus no surveillance. Although the adherence 
to screening was only 58% in the screened group, 
HCC mortality rate could be reduced to 37%. 
The second RCT was performed in 5,581 chronic 
HBV patients in China, with serum AFP repeated 
every six months.49 Although screening with 
semiannual AFP resulted in earlier diagnosis of 
HCC, but the overall mortality rate did not differ 
significantly between the screened group and 
control group, because therapy for the patients 
found by screening was ineffective.
Other studies on HCC surveillance were 
population and non-population-based cohorts 
and cost-effectiveness analysis, which mostly 
showed the advantage of surveillance to detect 
early-stage HCC.40,50-53 A meta-analysis of 
prospective cohort studies found that HCC 
surveillance using a combination of ultrasound 
and AFP was highly efficacious, with a sensitivity 
of 69% to detect HCCs at an early stage.25 
However, HCC surveillance does not give 
any benefit in advanced cirrhosis (Child-Pugh 
C patients) because their poor liver function 
adversely affects the overall mortality.52
HCC SURVEILLANCE IN REAL-LIFE 
PRACTICE
Although HCC surveillance has been 
proven to be efficacious in finding early-stage 
HCC, its utilization rates in real-life practice 
are low. A recent systematic review showed 
that pooled surveillance rate was only 18%.54 
The surveillance rates were significantly 
higher among patients followed in subspecialty 
Regular semiannual surveillance
Abnormal surveillance tests (detected nodule during
ultrasound or elevated levels of AFP, PIVKA-II or AFP-L3)
Triple-phase CT or MRI
Radiological hallmark of HCC:
enhancement in the arterial phase
and washout in the portal venous
or delayed phase (1)
No lesion
detected Stable in size
or disappearance
of nodule
MRI with
liver-specific
contrast
Increase of
nodule size or
level of
biomarkers
Biopsy or
MRI with liver-specific
contrast or CEUS
HCC confirmed
Yes No
Yes No
Treat as HCC
Follow-up three months
later using MRI with
liver-specific contrast
(if available), or triple-phase
CT/MRI, and biomarkers
(AFP, PIVKA-II, AFP L3)
Figure 1. Recall policy algorithm for patients with abnormal results during HCC surveillance tests. AFP: alpha-feto protein, AFP-L3: 
AFP lectin fraction, CEUS: contrast-enhanced ultrasonography, Gd-EOB-DTPA: gadolinium ethoxybenzyl diethylenetriamine 
pentaacetic acid, PIVKA-II: proteins induced by vitamin K absence-II.
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gastroenterology clinics compared to those 
followed in primary care clinics (51% vs 17%, 
respectively). Another retrospective study 
also found that even among patients closely 
followed by expert hepatologists in academic 
centers, nearly 30% of patients had inconsistent 
HCC surveillance.55 According to a web-based 
survey of primary care providers in USA, 
barriers to HCC surveillance included not being 
up-to-date with HCC guidelines, difficulties in 
communicating effectively with patients about 
HCC surveillance, and more important issues to 
manage in clinic.56
The Quality in the Continuum of Cancer 
Care conceptual model categorizes surveillance 
process failures as an (a) absence of screening, 
(b) absence of follow-up for abnormal tests, or (c) 
absence of detection despite completing screening 
and follow-up.57 Absence of surveillance, defined 
as lack of ultrasound performed for surveillance 
purposes within the 12-month period before 
HCC diagnosis, was found in 75% of patients.58 
Furthermore, failure of detection, defined as 
inability of ultrasound to detect suspicious lesion 
within the year prior to HCC diagnosis, was 
found in 11.4% of patients.58
In a recent retrospective study by Wong 
et al,59 ultrasound only detected 19% of single 
tumors less than 2 cm in diameter. There are 
several limitations of surveillance program 
using ultrasound. Coarse liver echotexture, 
obesity, thickened adipose tissue, increased waist 
circumference, uncooperative patient, a lot of 
bowel gas, and difficulty of position change due 
to limited patients’ movement, are some patients’ 
factors which can interfere an ultrasound exam. 
Furthermore, ultrasound exam is highly operator-
dependent and the result is related to operator 
skill and experience. To solve this problem, Kim 
et al suggests a screening strategy using MRI 
with liver-specific contrast.22 In this prospective 
study, 407 patients received paired ultrasound 
and MRI screenings. As a result, HCC detection 
rate of MRI was significantly higher than that of 
ultrasound (86% versus 27.9%, respectively). 
However, MRI with liver-specific contrast is 
costly and not widely available. It is still a 
long way before MRI can be applied as HCC 
surveillance test in daily practice.
There are several components involved 
in implementing HCC surveillance in clinical 
practice: (1) providers ability to identify high-risk 
patients, (2) providers referral for surveillance, 
(3) patients knowledge and acceptance about the 
tests, (4) health care system schedule of the tests, 
and (5) adherence of patients to surveillance 
recommendation.27 Furthermore, effective 
treatment for early-stage HCC patients should 
be available in order to make HCC surveillance 
program beneficial. An example of successful 
nationwide surveillance program is shown by 
Japan. Japan has succeeded in improving its HCC 
patients’ 5-year survival rate from 5.1% in 1978–
1980 to 42% in 2001–2005.60 One of the key for 
the success is the government involvement in 
preventive measures against HCC and hepatitis. 
Screening of individuals at high risk for HCC is 
covered by the national health insurance and the 
social insurance system.61
CONCLUSION
HCC surveillance tests should be performed 
in patients with cirrhosis and in adult patients 
with chronic hepatitis B, regardless of cirrhosis. 
Combination of ultrasound and tumor marker 
for HCC surveillance is recommended in a six-
month interval. Serum AFP is the most common 
tumor marker investigated for HCC surveillance 
and the efficacy of combination with other tumor 
markers (PIVKA-II and AFP-L3) for HCC 
surveillance needs further study. Implementation 
of HCC surveillance in real-world practice is a 
complex process and HCC surveillance is still 
underutilized. Value of HCC surveillance is 
also determined by the availability of effective 
treatment for early-stage HCC.
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